S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

$5.05
-0.02 (-0.39%)
(As of 04/16/2024 ET)
Today's Range
$5.03
$5.16
50-Day Range
$4.90
$5.37
52-Week Range
$4.26
$6.05
Volume
20,001 shs
Average Volume
7,888 shs
Market Capitalization
$39.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ICCC stock logo

About ImmuCell Stock (NASDAQ:ICCC)

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ICCC Stock Price History

ICCC Stock News Headlines

BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
See More Headlines
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/17/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:ICCC
Employees
74
Year Founded
N/A

Profitability

Net Income
$-5,780,000.00
Pretax Margin
-33.02%

Debt

Sales & Book Value

Annual Sales
$17.47 million
Book Value
$3.23 per share

Miscellaneous

Free Float
7,263,000
Market Cap
$39.14 million
Optionable
Not Optionable
Beta
0.59
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael F. Brigham (Age 63)
    President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
    Comp: $395.24k
  • Ms. Bobbi Jo Brockmann (Age 47)
    VP of Sales & Marketing and Director
    Comp: $323.52k
  • Elizabeth S. Toothaker
    Director of Finance & Administration and Controller
  • Mr. A. Gustavo Scaffa
    Senior Director of Quality
  • John W. Zinckgraf
    Director of Product Development

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed in 2024?

ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC shares have decreased by 0.8% and is now trading at $5.05.
View the best growth stocks for 2024 here
.

When is ImmuCell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ICCC earnings forecast
.

How can I listen to ImmuCell's earnings call?

ImmuCell will be holding an earnings conference call on Friday, May 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2581533".

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) announced its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company earned $5.10 million during the quarter. ImmuCell had a negative trailing twelve-month return on equity of 21.79% and a negative net margin of 33.05%.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICCC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners